Company news
Alector, Inc. news in 2022
Alector, Inc.'s news releases, calls and decks from 2022, newest first.
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 7, 2022
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
November 28, 2022
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
Alector Announces Promotion of Clare Hunt to Chief People Officer
October 12, 2022
Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)
September 11, 2022
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
August 3, 2022
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
May 26, 2022
Alector Reports First Quarter 2022 Financial Results and Provides Business Update
May 4, 2022
Alector to Participate at the BofA Securities 2022 Healthcare Conference
May 3, 2022
Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer
March 28, 2022
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
March 14, 2022
Alector to Present at Upcoming Healthcare Conferences
March 8, 2022
Alector to Present New AL001 Data at AD/PD™ 2022
March 7, 2022
Alector to Participate at the Cowen 42nd Annual Health Care Conference
February 28, 2022
Alector Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer
February 6, 2022